Indexing
CÁC SỐ TỪ 2011-2023
Tạp chí Y Dược Học
Abstract
Background: Biliary tract carcinoma (BTC) is an aggressive malignancy with poor prognosis and limited therapeutic options. Claudin 18.2 (CLDN18.2) has recently emerged as a promising therapeutic target; however, data regarding its expression in BTC remain limited.
Objectives: To determine the prevalence of CLDN18.2 expression and investigate its association with clinicopathological characteristics in patients with biliary tract carcinoma.
Materials and Methods: A retrospective, descriptive study was conducted on 83 histologically confirmed BTC cases (53 surgical resection specimens and 30 core needle biopsies), including gallbladder carcinoma (GBC), extrahepatic cholangiocarcinoma (eCCA), and intrahepatic cholangiocarcinoma (iCCA), collected from Cho Ray Hospital and the University Medical Center Ho Chi Minh City. CLDN18.2 expression was assessed by immunohistochemistry using the VENTANA CLDN18 (clone 43-14A) antibody. Positivity was defined as membranous staining of moderate-to-strong intensity (2+/3+) in ≥75% of tumor cells.
Results: The overall prevalence of CLDN18.2 expression was 19.3%. CLDN18.2 positivity was significantly more frequent in eCCA than in iCCA (55.6% vs. 15.1%, p = 0.020). Positivity rates in biopsy and surgical specimens were 23.3% (7/30) and 17.0% (9/53), respectively, with no significant difference (p = 0.566). Among surgical specimens (n=53), CLDN18.2 expression was not significantly associated with perineural invasion, lymphovascular invasion, or nodal metastasis (all p > 0.05).
Conclusions: CLDN18.2 is expressed in approximately one-fifth of BTC cases and is significantly more prevalent in extrahepatic cholangiocarcinoma, supporting further investigation of CLDN18.2-directed therapies in this subgroup. Given the heterogeneous expression pattern of CLDN18.2 and the fact that many patients with advanced-stage BTC lack surgical specimens, biopsy-based assessment remains a clinically relevant reference, although results should be interpreted cautiously and confirmed on surgical tissue when available.
| Published | 2026-10-14 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 17 No. ONLINE FIRST (2027) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2027.1.1229 | |
| Keywords | Biliary tract carcinoma, Claudin 18.2, immunohistochemistry, perineural invasion, targeted therapy Carcinôm đường mật, Claudin 18.2, hóa mô miễn dịch, xâm nhập thần kinh, điều trị nhắm đích |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428-444.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624-7634.
Angerilli V, Sacchi D, Rizzato M, Gasparello J, Ceccon C, Sabbadin M, et al. Claudin 18.2: a promising actionable target in biliary tract cancers. ESMO Open. 2025;10:105049.
Lee SM, Wang H. Claudin 18.2 testing in gastroesophageal and pancreatobiliary cancers: current status, clinical implications and challenges. Chin Clin Oncol. 2026;15(2):36.
Dominguez Wiscovitch A, Sanchez Mendez RJ, Chuy J. CLDN18.2-targeted therapy in gastrointestinal cancers. Cancers (Basel). 2025;17(23):3764.
Desai N, Ko HM, Lee M, Fazlollahi L, Moy RH, Yoon SS, et al. Claudin 18 immunohistochemistry in cholangiocarcinoma. J Gastrointest Oncol. 2025;16(2):671-678.
Kinzler MN, Gretser S, Schulze F, Bankov K, Abedin N, Bechstein WO, et al. Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre. Histopathology. 2024;86(4):640-646.
Kuo YH, Ong KH, Sun DP, Tian YF, Chou CL, Chan TC, et al. Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma. Virchows Arch. 2025;486:1199-1210.
Yu C, Pan Y, Li F, Guo Z, Xu D, Zhu Y, et al. Claudin18.2 defines a prognostically distinct subgroup of intrahepatic cholangiocarcinoma via CD8+ T-cell exclusion. Front Oncol. 2025;15:1636367.
Ni S-J, Wang X, Yuan L, Dong H, Sun H, Tan C, et al. Claudin18.2 expression in gallbladder cancer correlates with immune activation and a favourable prognosis. J Clin Pathol. 2025;jcp-2024-209914.
Yan P, Dong Y, Zhang F, Zhen T, Liang J, Shi H, et al. Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts. J Clin Pathol. 2024;jcp-2023-209268.
Fassan M, Kuwata T, Matkowskyj KA, Röcken C, Rüschoff J. Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach. Mod Pathol. 2024;37(11):100589.
Nagano S, Kurokawa Y, Hagi T, Motoyama Y, Saito T, Takahashi T, et al. Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer. Int J Clin Oncol. 2026;31:621-629.
Choi E, Shin J, Ryu MH, Kim HD, Park YS. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep. 2024;14(1):17648.
Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379-3391.